Skip to main content
Clinical Trials/NCT01134159
NCT01134159CompletedNot Applicable

Registry Experience at the WAshington Hospital CenteR, DeS - Taxus Liberte vs Xience V

Medstar Health Research Institute10 sites in 1 country1,200 target enrollmentStarted: June 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
1,200
Locations
10
Primary Endpoint
Major adverse cardiac events,

Study Overview

Brief Summary

Multicenter, retrospective registry to collect 9-12 month follow-up data to evaluate major adverse cardiac events in patients whom have undergone percutaneous coronary intervention and received either Taxus Liberte or Xience V.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients 18 years of age or older, both genders
  • Underwent PCI with Taxus Liberte (alone) or Xience (alone)

Exclusion Criteria

  • Underwent PCI with a non-Taxus Liberte or Xience V DES during the same procedure
  • Received both Taxus-Liberte and Xience-V during the same index procedure
  • Patients not taking, or unable to take, dual antiplatelet therapy (aspirin plus clopidogrel or prasugrel).

Outcomes

Primary Outcomes

Major adverse cardiac events,

Time Frame: 1 year

A composite of all-cause death, Q-wave myocardial infarction, and target vessel revascularization

Secondary Outcomes

  • Stent thrombosis(1 year)
  • Target vessel revascularization(1 year)
  • Cardiac death(1 year)

Investigators

Sponsor
Medstar Health Research Institute
Sponsor Class
Other

Study Sites (10)

Loading locations...

Similar Trials